Bio

Clinical Focus


  • Psychotherapy and psychopharmacology, Time-limited Dynamic Psychotherapy, Women's issues.
  • Psychiatry

Academic Appointments


Professional Education


  • Internship:Santa Clara Valley Medical Center (1993) CA
  • Medical Education:Stanford University School of Medicine (1992) CA
  • MPH, Columbia University School of Public Health, Maternal & Child Health (1986)
  • Residency:Stanford University School of Medicine (1996) CA
  • Board Certification: Psychiatry, American Board of Psychiatry and Neurology (2000)

Research & Scholarship

Projects


  • Flipped Classroom/Team-based Learning Project., Stanford University (3/1/2013)

    Development of a flipped classroom combined with Team Based Learning methods within a previously, traditionally taught PGY II Psychopharm/psychopathology 9-month course in the Department of Psychiatry. VPOL funded.

    Location

    Department of Psychiatry and Behavioral Sciences, Stanford, CA

Teaching

2010-11 Courses


Publications

Journal Articles


  • Job Satisfaction Among Associate Training Directors in Psychiatry: A Bimodal Distribution ACADEMIC PSYCHIATRY Arbuckle, M. R., DeGolia, S. G., Esposito, K., Weinberg, M., Brenner, A. M. 2013; 37 (2): 129-130

    View details for Web of Science ID 000316155900017

    View details for PubMedID 23475249

  • Associate Residency Training Directors in Psychiatry: Demographics, Professional Activities, and Job Satisfaction ACADEMIC PSYCHIATRY Arbuckle, M. R., DeGolia, S. G., Esposito, K., Miller, D. A., Weinberg, M., Brenner, A. M. 2012; 36 (5): 391-394

    Abstract

    The purpose of this study was to characterize associate training director (ATD) positions in psychiatry.An on-line survey was e-mailed in 2009 to all ATDs identified through the American Association of Directors of Psychiatric Residency Training (AADPRT). Survey questions elicited information regarding demographics, professional activities, job satisfaction, and goals.Of 170 ATDs surveyed, 73 (42.9%) completed the survey. Most respondents (71.3%) had been in their positions for 3 years or less. Many ATDs indicated that they were involved in virtually all aspects of residency training; 75% of respondents agreed that they were happy with their experience. However, specific concerns included inadequate time and compensation for the ATD role in addition to a lack of mentorship and unclear job expectations.Thoughtful attention to the construction of the ATD role may improve job satisfaction.

    View details for Web of Science ID 000308454500010

    View details for PubMedID 22983471

  • Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression JOURNAL OF AFFECTIVE DISORDERS Winsberg, M. E., DeGolia, S. G., Strong, C. M., Ketter, T. A. 2001; 67 (1-3): 207-212

    Abstract

    There have been few systematic studies of the treatment of bipolar II depression. While divalproex sodium (DVPX) is effective in acute mania, there are few data on the antidepressant effects of DVPX. Similarly, little is known regarding the use of DVPX administered in a single daily dose.We performed a 12-week open trial of DVPX monotherapy (mean dose 882 mg qhs, mean level 80.7 mug/ml) in nineteen (thirteen women, six men, mean age 29) bipolar II depressed outpatients. Eleven patients (six women, five men) were medication-naive (MN) and eight (seven women, one man) were mood stabilizer-naive (MSN), having had prior trials of antidepressants or stimulants. Mean illness and current depressive episode duration were 15.4 years and 11.8 weeks, respectively. DVPX was given as a single dose each evening starting with 250 mg at bedtime and increased by 250 mg at bedtime every 4 days until symptom relief or adverse effects were noted. Weekly prospective Hamilton Depression, Young Mania and Clinical Global Impression ratings were obtained.DVPX therapy was generally well tolerated. Twelve of nineteen patients (63%) responded (>50% decrease in Hamilton Depression ratings). MN patients compared to MSN patients tended to have a higher response rate (9/11 versus 3/8, P<0.08). Mean Hamilton scores decreased from 22.2 to 9.6 (P<0.0001) in the entire group, from 20.6 to 6.6 (P<0.0003) in MN patients, and from 24.2 to 14.7 (P=0.008) in MSN patients.Single daily dose DVPX monotherapy appeared to be well tolerated and substantially benefited 63% of patients with bipolar II depression. The trend towards a higher rate of antidepressant response to DVPX in MN patients (82%) compared to MSN patients (38%) could be due to a milder form or earlier phase of illness and the lack of prior medication exposure or failures. This uncontrolled open pilot study must be viewed with caution, and randomized double-blind placebo controlled studies of DVPX in bipolar II depression are warranted to confirm the possibility that single daily dose DVPX is an effective, well-tolerated, first-line monotherapy in this population.

    View details for Web of Science ID 000174633800023

    View details for PubMedID 11869770

  • Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states JOURNAL OF CLINICAL PSYCHIATRY Ketter, T. A., Winsberg, M. E., DeGolia, S. G., Dunai, M., Tate, D. L., Strong, C. M. 1998; 59 (2): 83-85

    View details for Web of Science ID 000072288800011

    View details for PubMedID 9501894

Footer Links:

Stanford Medicine Resources: